Press releases
Biofidelity to present ASPYRE®-Lung data at AACR 2024
Apr 5. 2024
Biofidelity announced that new data from its breakthrough product ASPYRE-Lung will be presented in three scientific posters, including a Late Breaking Abstract (LBA) at AACR 2024.
Biofidelity raises $24 million in new financing to accelerate commercialization and expand product pipeline
Apr 3. 2024
Biofidelity successfully completed a financing round totalling $24 million bringing total funding raised since the Company was founded in 2019 to $60 million.
Fidelis Sustainability Distribution and Biofidelity Collaborate to Bring Rapid Precision Genomic Testing to Veterans Administration (VA) Customers
Jan 24. 2024
Biofidelity and Fidelis Sustainability Distribution (Fidelis) today announced that they have entered into an agreement to make ASPYRE®-Lung available to VA Medical Centers and active military institutions across the US.
News
Biofidelity’s $24m boost is set to reframe diagnostic testing for lung cancer
Apr 12. 2024
Biofidelity’s successful $24million financing round, which brings the total funding raised to $60m since being founded in 2019, will accelerate the growth of its game-changing ASPYRE-Lung genomic testing protocol.
Biofidelity Highlights Consistency, Accessibility of Lung Cancer Mutation Assay
Apr 12. 2024
Cancer molecular diagnostics company Biofidelity this week presented the results of three studies the American Association for Cancer Research (AACR) annual meeting showcasing the consistency, reproducibility, and superiority in certain sample types of its ASPYRE-Lung cancer mutation detection assay compared to nextgeneration sequencing (NGS).
Research Triangle-based Biofidelity raises $24 million
Apr 5. 2024
Biofidelity, a genomic technology company with headquarters in the Research Triangle Park, has raised $24 million from investors in a new round of funding.